CLINICAL ROLE OF F-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY FOR DETECTION AND MANAGEMENT OF RENAL CELL CARCINOMA

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Sep 2001CLINICAL ROLE OF F-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY FOR DETECTION AND MANAGEMENT OF RENAL CELL CARCINOMA SHAKHER RAMDAVE, GWYNNE W. THOMAS, SALVATORE U. BERLANGIERI, DAMIEN M. BOLTON, IAN DAVIS, HENRI-TOCHON- DANGUY, DUNCAN MACGREGOR, and ANDREW M. SCOTT SHAKHER RAMDAVESHAKHER RAMDAVE , GWYNNE W. THOMASGWYNNE W. THOMAS , SALVATORE U. BERLANGIERISALVATORE U. BERLANGIERI , DAMIEN M. BOLTONDAMIEN M. BOLTON , IAN DAVISIAN DAVIS , HENRI-TOCHON- DANGUYHENRI-TOCHON- DANGUY , DUNCAN MACGREGORDUNCAN MACGREGOR , and ANDREW M. SCOTTANDREW M. SCOTT View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)65845-4AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We evaluate the accuracy of F-18 fluorodeoxyglucose (FDG)-positron emission tomography (PET) for staging and management of renal cell carcinoma. Materials and Methods: FDG-PET was performed in 25 patients with known or suspected primary renal tumors and/or metastatic disease and compared with conventional imaging techniques, including computerized tomography (CT). Histopathological confirmation was obtained in 18 patients and confirmation of the disease was by followup in the remainder. The impact of FDG-PET on disease management was also assessed. Results: Of the 17 patients with known or suspected primary tumors FDG-PET was true positive in 15, true negative in 1 and false-negative in 1. Comparative CT was true positive in 16 patients and false-positive in 1. The accuracy of FDG-PET and CT was similar (94%). All patients would have undergone radical nephrectomy after conventional imaging findings but FDG-PET results altered treatment decisions for 6 (35%), of whom 3 underwent partial nephrectomy and 3 avoided surgery due to confirmation of benign pathology or detection of unsuspected metastatic disease. Of the 8 cases referred for evaluation of local recurrence and/or metastatic disease FDG-PET changed treatment decisions in 4 (50%), with disease up staged in 3 and recurrence excluded in 1. Compared with CT, FDG-PET was able to detect local recurrence and distant metastases more accurately and differentiated recurrence from radiation necrosis. Conclusions: FDG-PET accurately detected local disease spread and metastatic disease in patients with renal cell carcinoma and altered treatment in 40%. FDG-PET may have a role in the diagnostic evaluation of patients with renal cell carcinoma preoperatively and staging of metastatic disease. References 1 : Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med1999; 40: 591. Google Scholar 2 : F-18 Fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer. Eur J Cardiothorac Surg1999; 16: S25. Google Scholar 3 : Tumor imaging and therapy. In: Nuclear Medicine. Radiologic Clinics of North America. Edited by . New York: W. B. Saunders Co.1993: 859. Google Scholar 4 : Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med1996; 23: 1641. Google Scholar 5 : Positron emission tomography in colorectal carcinoma. Diagn Oncol1995; 4: 123. Google Scholar 6 : Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol1996; 14: 700. Google Scholar 7 : The role of positron emission tomography in assessing response to neoadjuvant chemotherapy for non-small-cell lung cancer. Med J Aust1998; 169: 227. Google Scholar 8 : PET scanning in head and neck oncology: a review. Head Neck1998; 20: 208. Google Scholar 9 : Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res1996; 6: 325. Google Scholar 10 : Renal cell carcinoma: survival and prognostic factors. Urology1986; 27: 291. Google Scholar 11 : The diagnosis and treatment of renal cell carcinoma. Cancer1980; 45: 1947. Google Scholar 12 : Histopathologic prognostic indicators for renal cell carcinoma. Semin Diagn Pathol1998; 15: 68. Google Scholar 13 : The results of radical nephrectomy for renal cell carcinoma. J Urol1969; 101: 297. Link, Google Scholar 14 : Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol1982; 6: 655. Crossref, Medline, Google Scholar 15 : Renal-cell carcinoma. N Engl J Med1996; 335: 865. Google Scholar 16 : Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: pilot animal and human studies. J Urol1991; 146: 1470. Abstract, Google Scholar 17 : Correlation between visualization of primary renal cancer by FDG-PET and histopathological findings. J Nucl Med1996; 37: 64P. Google Scholar 18 : Renal oncocytomas. Abdom Imaging1998; 23: 249. Google Scholar 19 : Conservative surgery for renal cell carcinoma: a single-center experience with 100 patients. J Urol1989; 141: 835. Link, Google Scholar 20 : Expanding indications for conservative renal surgery in renal cell carcinoma. Urology1994; 43: 160. Google Scholar 21 : Renal cell carcinoma: clinical aspects, imaging diagnosis, and staging. Semin Roentgenol1995; 30: 128. Google Scholar 22 : Preoperative lymph node staging in patients with kidney and urinary bladder neoplasm. J Nucl Med1994; 35: 223P. Google Scholar 23 : Resection of metastatic renal cell carcinoma. J Clin Oncol1998; 16: 2261. Google Scholar From the Department of Nuclear Medicine and Centre for PET, Departments of Nephrology, Urology and Anatomical Pathology, Ludwig Institute Oncology Unit and Tumour Targeting Program, Ludwig Institute for Cancer Research, Austin & Repatriation Medical Centre, Heidelberg, Australia© 2001 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byBouchelouche K and Oehr P (2007) Positron Emission Tomography and Positron Emission Tomography/Computerized Tomography of Urological Malignancies: An Update ReviewJournal of Urology, VOL. 179, NO. 1, (34-45), Online publication date: 1-Jan-2008.KANG D, WHITE R, ZUGER J, SASSER H and TEIGLAND C (2018) Clinical Use of Fluorodeoxyglucose F 18 Positron Emission Tomography for Detection of Renal Cell CarcinomaJournal of Urology, VOL. 171, NO. 5, (1806-1809), Online publication date: 1-May-2004. Volume 166Issue 3September 2001Page: 825-830 Advertisement Copyright & Permissions© 2001 by American Urological Association, Inc.Keywordstomography, emission-computedfluorodeoxyglucose F-18carcinoma, renal cellMetricsAuthor Information SHAKHER RAMDAVE More articles by this author GWYNNE W. THOMAS More articles by this author SALVATORE U. BERLANGIERI More articles by this author DAMIEN M. BOLTON More articles by this author IAN DAVIS More articles by this author HENRI-TOCHON- DANGUY More articles by this author DUNCAN MACGREGOR More articles by this author ANDREW M. SCOTT More articles by this author Expand All Advertisement PDF downloadLoading ...